Celldex Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.59) Per Share, HC Wainwright Forecasts (NASDAQ:CLDX)

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Stock analysts at HC Wainwright upped their Q2 2024 earnings per share estimates for Celldex Therapeutics in a research note issued on Tuesday, May 7th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will post earnings of ($0.59) per share for the quarter, up from their prior estimate of ($0.67). HC Wainwright currently has a “Buy” rating and a $80.00 target price on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.85) per share. HC Wainwright also issued estimates for Celldex Therapeutics’ Q3 2024 earnings at ($0.60) EPS, Q4 2024 earnings at ($0.60) EPS, FY2024 earnings at ($2.34) EPS and FY2025 earnings at ($2.67) EPS.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.19. Celldex Therapeutics had a negative return on equity of 41.06% and a negative net margin of 2,054.46%. The company had revenue of $4.13 million for the quarter, compared to analyst estimates of $1.20 million.

A number of other research analysts also recently issued reports on the stock. Guggenheim raised their price target on shares of Celldex Therapeutics from $72.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a report on Friday, March 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Celldex Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $66.00.

Celldex Therapeutics Stock Performance

NASDAQ:CLDX opened at $41.21 on Thursday. The company has a market capitalization of $2.30 billion, a price-to-earnings ratio of -14.16 and a beta of 1.60. The stock has a 50-day simple moving average of $41.71 and a 200 day simple moving average of $37.03. Celldex Therapeutics has a one year low of $22.11 and a one year high of $53.18.

Institutional Trading of Celldex Therapeutics

Several institutional investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC lifted its holdings in Celldex Therapeutics by 70.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,941 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 805 shares during the last quarter. Strs Ohio boosted its holdings in Celldex Therapeutics by 92.9% during the fourth quarter. Strs Ohio now owns 2,700 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 1,300 shares in the last quarter. Headlands Technologies LLC acquired a new position in Celldex Therapeutics in the first quarter worth approximately $147,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Celldex Therapeutics by 36.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,582 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 1,746 shares in the last quarter. Finally, Aigen Investment Management LP bought a new stake in shares of Celldex Therapeutics during the 4th quarter worth $251,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.